Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 1998 Aug;74(4):265–270. doi: 10.1136/sti.74.4.265

Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial

E T Katabira, N K Sewankambo, R D Mugerwa, E M Belsey, F X Mubiru, C Othieno, P Kataaha, M Karam, M Youle, J H Perriens, J M Lange
PMCID: PMC1758122  PMID: 9924466

Abstract

BACKGROUND: Interferon alfa (IFN-alpha) exhibits dose related in vitro activity against human immunodeficiency virus (HIV), with complete inhibition of HIV replication at IFN-alpha concentrations > or = 256 IU/ml. In mid-1990, Kenyan investigators reported that oral administration of an extremely low dose (150 IU/day) of natural human (nHu) IFN-alpha resulted in complete alleviation of AIDS related complex and AIDS symptoms and resolution of opportunistic infections without additional treatment. Moreover, loss of HIV antibody seropositivity was reported in approximately 10% of treated patients. Subsequent small studies failed to substantiate these spectacular claims, but controversy on the efficacy of this treatment persisted. METHODS: We studied 559 adult Ugandan patients with WHO stage 2-4 HIV infection and a Karnofsky performance score of more than 50, who had not received any drugs with antiretroviral activity in the previous 3 months. The patients were randomly assigned in a double blind fashion either to 150 IU oral nHuIFN-alpha/day or placebo. The duration of treatment was extended from 28 weeks to 60 weeks 9 months after enrollment had started. At that time 112 subjects had already received 28 weeks of treatment and been discontinued from the study. RESULTS: Both study groups were comparable with respect to all baseline characteristics studied, except that the nHuIFN-alpha group had slightly lower absolute CD4+ lymphocyte counts (median 60.7 x 10(6)/l) than the placebo group (median 85.3 x 10(6)/l) (p = 0.033). Therefore, all analyses were adjusted for CD4+ lymphocyte counts at entry. In both treatment groups there was relentless progression of HIV disease. Subjects treated with nHuIFN-alpha and placebo had similar mortality, disease progression rates, decline of CD4+ lymphocyte counts and Karnofsky performance scores, and prevalence of symptoms. No patient reverted to HIV-1 seronegative antibody status. Serious adverse events were not seen. Quality control of the study medication documented that the active drug indeed contained IFN-alpha activity. CONCLUSIONS: The current large, randomised, double blind, placebo controlled study did not show any benefit from oral treatment with 150 IU nHuIFN-alpha/day in a population of African patients with symptomatic HIV infection. 






Full Text

The Full Text of this article is available as a PDF (139.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hartshorn K. L., Neumeyer D., Vogt M. W., Schooley R. T., Hirsch M. S. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses. 1987 Summer;3(2):125–133. doi: 10.1089/aid.1987.3.125. [DOI] [PubMed] [Google Scholar]
  2. Hartshorn K. L., Vogt M. W., Chou T. C., Blumberg R. S., Byington R., Schooley R. T., Hirsch M. S. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother. 1987 Feb;31(2):168–172. doi: 10.1128/aac.31.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ho D. D., Hartshorn K. L., Rota T. R., Andrews C. A., Kaplan J. C., Schooley R. T., Hirsch M. S. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet. 1985 Mar 16;1(8429):602–604. doi: 10.1016/s0140-6736(85)92144-0. [DOI] [PubMed] [Google Scholar]
  4. Hulton M. R., Levin D. L., Freedman L. S. Randomized, placebo-controlled, double-blind study of low-dose oral interferon-alpha in HIV-1 antibody positive patients. J Acquir Immune Defic Syndr. 1992;5(11):1084–1090. [PubMed] [Google Scholar]
  5. Johnston M. D., Finter N. B., Young P. A. Dye uptake method for assay of interferon activity. Methods Enzymol. 1981;78(Pt A):394–399. doi: 10.1016/0076-6879(81)78147-3. [DOI] [PubMed] [Google Scholar]
  6. Kaiser G., Jaeger H., Birkmann J., Poppinger J., Cummins J. M., Gallmeier W. M. Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563–569. doi: 10.1097/00002030-199206000-00007. [DOI] [PubMed] [Google Scholar]
  7. Koech D. K., Obel A. O. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). East Afr Med J. 1990 Jul;67(7 Suppl 2):SS64–SS70. [PubMed] [Google Scholar]
  8. Kornbluth R. S., Oh P. S., Munis J. R., Cleveland P. H., Richman D. D. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med. 1989 Mar 1;169(3):1137–1151. doi: 10.1084/jem.169.3.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lane H. C., Davey V., Kovacs J. A., Feinberg J., Metcalf J. A., Herpin B., Walker R., Deyton L., Davey R. T., Jr, Falloon J. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med. 1990 Jun 1;112(11):805–811. doi: 10.7326/0003-4819-112-11-805. [DOI] [PubMed] [Google Scholar]
  10. Lane H. C., Kovacs J. A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J. A., Baseler M., Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218–1222. doi: 10.1016/s0140-6736(88)90811-2. [DOI] [PubMed] [Google Scholar]
  11. Lisse I. M., Whittle H., Aaby P., Normark M., Gyhrs A., Ryder L. P. Labelling of T cell subsets under field conditions in tropical countries. Adaptation of the immuno-alkaline phosphatase staining method for blood smears. J Immunol Methods. 1990 May 8;129(1):49–53. doi: 10.1016/0022-1759(90)90419-v. [DOI] [PubMed] [Google Scholar]
  12. Orholm M., Pedersen C., Mathiesen L., Dowd P., Nielsen J. O. Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study. AIDS. 1989 Feb;3(2):97–100. doi: 10.1097/00002030-198902000-00008. [DOI] [PubMed] [Google Scholar]
  13. Poli G., Orenstein J. M., Kinter A., Folks T. M., Fauci A. S. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science. 1989 May 5;244(4904):575–577. doi: 10.1126/science.2470148. [DOI] [PubMed] [Google Scholar]
  14. Sperber S. J., Gocke D. J., Haberzettl C. A., Pestka S. Low-dose oral recombinant interferon-alpha A in patients with HIV-1 infection: a blinded pilot study. AIDS. 1993 May;7(5):693–697. [PubMed] [Google Scholar]
  15. Yamada O., Hattori N., Kurimura T., Kita M., Kishida T. Inhibition of growth of HIV by human natural interferon in vitro. AIDS Res Hum Retroviruses. 1988 Aug;4(4):287–294. doi: 10.1089/aid.1988.4.287. [DOI] [PubMed] [Google Scholar]
  16. Yamamoto J. K., Barré-Sinoussi F., Bolton V., Pedersen N. C., Gardner M. B. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res. 1986 Apr;6(2):143–152. doi: 10.1089/jir.1986.6.143. [DOI] [PubMed] [Google Scholar]
  17. de Wit R., Schattenkerk J. K., Boucher C. A., Bakker P. J., Veenhof K. H., Danner S. A. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214–1217. doi: 10.1016/s0140-6736(88)90810-0. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES